BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clin Ther 2018;40:2006-2020.e2. [PMID: 30477789 DOI: 10.1016/j.clinthera.2018.10.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020;38:607-18. [DOI: 10.1007/s40273-020-00896-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 de Vries FE, Godthelp A, Spruit JR, Ruissen AM, Tesselaar MET, Boekhout AH. Coping with social consequences of disease-related symptoms in patients with a metastatic small intestinal neuroendocrine tumour: A qualitative study. J Neuroendocrinol 2021;33:e12956. [PMID: 33733525 DOI: 10.1111/jne.12956] [Reference Citation Analysis]
3 Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-60. [PMID: 32272208 DOI: 10.1016/j.annonc.2020.03.304] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 43.0] [Reference Citation Analysis]
4 Bader M. Inhibition of serotonin synthesis: A novel therapeutic paradigm. Pharmacol Ther 2020;205:107423. [PMID: 31629717 DOI: 10.1016/j.pharmthera.2019.107423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
6 Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol 2020;2020:8341426. [PMID: 32322270 DOI: 10.1155/2020/8341426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Rinke A, Maintz C, Müller L, Weber MM, Lahner H, Pavel M, Saeger W, Houchard A, Ungewiss H, Petersenn S. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. Exp Clin Endocrinol Diabetes 2021;129:500-9. [PMID: 34293802 DOI: 10.1055/a-1342-2755] [Reference Citation Analysis]
8 Cantone MC, Dicitore A, Vitale G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. J Clin Med 2021;10:501. [PMID: 33535394 DOI: 10.3390/jcm10030501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021; 13(3): 231-255 [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp OR, Fountain D. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World J Gastroenterol 2020; 26(25): 3686-3711 [PMID: 32742136 DOI: 10.3748/wjg.v26.i25.3686] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Eur J Cancer 2021;144:200-14. [PMID: 33370645 DOI: 10.1016/j.ejca.2020.11.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Watanabe H, Ide R, Yamazaki Y, Fujishima F, Kasajima A, Yazdani S, Tachibana T, Motoi F, Unno M, Sasano H. Quantitative digital image analysis of somatostatin receptor 2 immunohistochemistry in pancreatic neuroendocrine tumors. Med Mol Morphol 2021. [PMID: 34247274 DOI: 10.1007/s00795-021-00294-6] [Reference Citation Analysis]
13 Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 2021. [PMID: 34378163 DOI: 10.1007/s40273-021-01071-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Abou Jokh Casas E, Pubul Núñez V, Anido-Herranz U, del Carmen Mallón Araujo M, del Carmen Pombo Pasín M, Garrido Pumar M, Cabezas Agrícola JM, Cameselle-Teijeiro JM, Hilal A, Ruibal Morell Á. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World J Gastroenterol 2020; 26(13): 1513-1524 [PMID: 32308351 DOI: 10.3748/wjg.v26.i13.1513] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Altieri B, Di Dato C, Modica R, Bottiglieri F, Di Sarno A, Pittaway JFH, Martini C, Faggiano A, Colao A. Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. Nutrients 2020;12:E1021. [PMID: 32276412 DOI: 10.3390/nu12041021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]